+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prognostic significance of pre- and postoperative glasgow prognostic score for patients with non-small cell lung cancer



Prognostic significance of pre- and postoperative glasgow prognostic score for patients with non-small cell lung cancer



Anticancer Research 34(6): 3137-3140



Our previous study showed the prognostic impact of preoperative Glasgow prognostic score (GPS) in patients who underwent resection for non-small cell lung cancer (NSCLC). In the present study, the relationship between postoperative GPS and prognosis was also examined in patients with NSCLC with preoperative GPS 1 or 2. Three hundred and twelve consecutive patients resected for NSCLC with a follow-up period of more than five years were enrolled. The GPS was calculated as follows: patients with elevated C-reactive protein level (>1.0 mg/dl) and hypoalbuminemia (<3.5 g/dl) were assigned to GPS 2. Patients with one or no abnormal value were assigned to GPS 1 or GPS 0. Study patients were allocated as follows: 264 (84.62%) to GPS 0; 31 (9.94%) to GPS 1; and 17 (5.45%) to GPS 2. The prognosis of the patients with preoperative GPS 2 was significantly poorer. Postoperative GPS was also examined for 48 patients with preoperative GPS 1 or 2. In 30/48 patients, postoperative GPS was improved to GPS 0, however, the postoperative GPS of the remaining 18 patients did not change to GPS 0. The 5-year survival of patients with postoperative GPS 0 and 1-2 were 73.02% and 11.11%, respectively. Preoperative GPS may be useful for postoperative prognosis of patients with NSCLC. Furthermore, persistently high GPS after surgery indicates poor prognosis in patients with NSCLC.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 055212877

Download citation: RISBibTeXText

PMID: 24922684


Related references

Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 142(6): 1285-1297, 2016

Comparison of Glasgow prognostic score and prognostic index in patients with advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 141(3): 563-568, 2015

Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer. Journal of Cancer Research and Therapeutics 12(2): 945-951, 2017

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer. Lung Cancer 8: 249-257, 2017

The Glasgow prognostic score as a prognostic factor in patients with advanced non-small cell lung cancer treated with cisplatin-based first-line chemotherapy. Journal of ChemoTherapy 27(1): 35-39, 2015

Value of the Glasgow Prognostic Score as a Prognostic Factor in Resectable Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 11(8): 1311-1318, 2016

P75 Prognostic Implications Of The Modified Glasgow Prognostic Score In Early Stage Non-small Cell Lung Cancer. Thorax 69(Suppl 2): A108-A109, 2014

Modified glasgow prognostic score in patients with small-cell lung cancer. Molecular and Clinical Oncology 7(1): 121-124, 2017

Prognostic Value of the Glasgow Prognostic Score or Modified Glasgow Prognostic Score for Patients with Colorectal Cancer Receiving Various Treatments: a Systematic Review and Meta-Analysis. Cellular Physiology and Biochemistry 51(3): 1237-1249, 2018

Glasgow prognostic score in patients receiving chemotherapy for non-small-cell lung cancer in stages IIIb and IV. Medical Archives 68(2): 83-85, 2014

Significance of the Glasgow Prognostic Score as a prognostic indicator for lung cancer surgery. Interactive Cardiovascular and Thoracic Surgery 21(5): 637-643, 2015

Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer. Journal of Thoracic Oncology 7(4): 655-662, 2012

The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer. Bmc Cancer 15: 386, 2015

The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. Journal of Clinical Pathology 60(6): 705-708, 2007

The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor in patients with resectable gastric cancer. Oncology 87(4): 205-214, 2014